<DOC>
	<DOC>NCT01910181</DOC>
	<brief_summary>This open-label, multicenter study will evaluate the pharmacokinetics, safety and efficacy of vemurafenib in Chinese participants with BRAF V600 mutation-positive unresectable or metastatic melanoma. Participants will receive vemurafenib 960 milligrams (mg) orally twice daily until disease progression or unacceptable toxicity occurs.</brief_summary>
	<brief_title>A Study of Vemurafenib (Zelboraf) in Chinese Participants With BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Chinese male or female participants, greater than or equal to (≥) 18 years of age Histologically confirmed metastatic melanoma (surgically unresectable Stage IIIC or Stage IV, American Joint Committee on Cancer) Treatmentnaïve or having received prior systemic treatments for metastatic melanoma Positive BRAF V600 mutation result determined by a designated laboratory using the Cobas 4800 BRAF V600 Mutation Test Measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 Previous allowed chemotherapy, immunotherapy, or radiation therapy must have been completed at least 2 weeks prior to study drug administration, and all associated toxicity must be resolved (to less than or equal to [≤] Grade 1 or baseline) Recovery from effects of any major surgery (excluding tumor biopsy at baseline) or significant traumatic injury at least 14 days before the first dose of study treatment Adequate hematologic, renal, and liver function as defined by protocol Fertile men and women must use an effective method of contraception during treatment and for ≥6 months after completion of treatment as directed by their physician (in accordance with local requirements). Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Life expectancy greater than (&gt;) 3 months Able to swallow pills Active central nervous system (CNS) lesions (radiographically unstable/symptomatic lesions), except participants treated with stereotactic therapy or surgery who remain without evidence of disease progression in brain for ≥3 months and have been off corticosteroid and anticonvulsant therapy for ≥3 weeks History of or known spinal cord compression or carcinomatous meningitis Anticipated or ongoing administration of anticancer therapies other than those administered in this study Active squamous cell carcinoma (SCC) that has not been excised or has not yet adequately healed post excision Pregnant or lactating women Refractory nausea and vomiting, malabsorption, external biliary shunt, or significant small bowel resection that would preclude adequate vemurafenib absorption Any of the following within the 6 months prior to study drug administration: myocardial infarction, severe/unstable angina, coronary/peripheral artery bypass graft, symptomatic congestive heart failure, serious cardiac arrhythmia requiring medication, uncontrolled hypertension, cerebrovascular accident or transient ischemic attack, or symptomatic pulmonary embolism Known clinically significant active infection History of allogeneic bone marrow transplantation or organ transplantation Previous malignancy within the past 5 years other than adequately treated basal cell carcinoma or SCC of the skin, melanoma insitu, and carcinoma insitu of the cervix and/or curatively treated cancer from which the participant is currently diseasefree, or any malignancy from which the participant has been continuously diseasefree for at least 5 years Previous treatment with a BRAF inhibitor (sorafenib allowed) or MEK inhibitor Participants who have had one or more doses of vemurafenib in a previous clinical trial Known human immunodeficiency virus (HIV) positivity or acquired immune deficiency syndrome (AIDS)related illness, or hepatitis B virus or hepatitis C virus (HCV) carriers (hepatitis B surface antigenpositive, HCV antibodypositive) Received any investigational treatment within 4 weeks of study drug start</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>